semaglutide discontinued Demand Rising for 'Bootlegged' Weight-Loss Drug Novo Nordisk's semaglutide shortage officially

One such treatment gaining popularity is Ozempic, a GLP-1 receptor agonist designed to aid in both diabetes management and weight loss

For suspected loss of efficacy: Verify medication storage, handling, and injection technique Review adherence patterns and timing of doses Assess for other factors affecting treatment response (dietary changes, new medications, intercurrent illness) Consider dose optimization within approved ranges if not already at maximum dose Evaluate alternative explanations for treatment failure If treatment failure persists despite addressing these factors, options include: Switching to an alternative GLP-1 receptor agonist (semaglutide, dulaglutide) or other therapy For diabetes management: considering ADA-recommended alternatives such as metformin optimization, SGLT2 inhibitors, or basal insulin For weight management: exploring other FDA-approved anti-obesity medications Intensifying lifestyle interventions and behavioral support For suspected hypersensitivity reactions: Immediate discontinuation of tirzepatide is warranted for any signs of serious hypersensitivity, including urticaria, angioedema, difficulty breathing, or anaphylaxis

Vomiting (also very common) may accompany nausea in some cases

The combined risk is whatever prednisone alone causes